NEIS JOHN 4

What Happened

• John Neis, a director of Cellectar Biosciences, was granted a derivative award of 25,000 shares on July 7, 2026. The Form 4 reports an acquisition at $0.00 (no cash paid at grant) and a reported value of $0 for the immediate transaction. This is an equity award (derivative) rather than an open-market purchase or sale — a typical way companies compensate and align directors with shareholders.

Key Details

• Transaction date: 2026-07-07; Form 4 filed: 2026-07-08 (timely).
• Transaction type/code: Award/Grant (A) — derivative equity grant reported as acquired at $0.00.
• Amount granted: 25,000 shares (derivative). Reported immediate cash value: $0.
• Vesting: The award “shall vest in full on July 7, 2027,” subject to continued service (per footnote).
• Shares owned after transaction: Not specified in the data provided in this summary.
• No sale or exercise occurred; this is not a cashless exercise or disposition.

Context

• This is a grant of derivative equity to a director that vests after one year; such awards are common for long-term alignment and do not reflect an immediate purchase or sale of stock. Because it’s a grant (not a sale), it does not signal a change in insider selling behavior.